S533 Impact of Computer-Aided Detection on Adenoma Detection Rate: A Single-Center Gastroenterology Analysis

Introduction: Artificial intelligence (AI) has emerged as a promising tool to address operator-dependent variations in colonoscopy quality, a critical factor in colorectal cancer prevention. Among AI applications, computer-aided detection (CADe) systems have demonstrated their potential to enhance adenoma detection rate (ADR) and adenomas per colonoscopy (APC) in controlled clinical settings, as evidenced by multiple randomized controlled trials. This investigation aims to review ADR in a busy, single-center outpatient gastroenterology practice in Fredericksburg, Virginia after implementing Medtronic’s GI Genius CADe system. Methods: We analyzed ADR data over 2022 and 2023 for 10 practitioners in a single-center outpatient gastroenterology practice. The CADe system was introduced in Q4 of 2022. Results: During Q1 to Q3 of 2022, the overall ADR was 33%. During Q4 of 2022, where there was partial use of the CADe system, ADR was 41%. In Q1 to Q4 of 2023 average ADR was 40% for all operators. Conclusion: Overall, ADR goals as a quality indicator for colonoscopy has been established to be ≥25% in the general population (typically ≥30% in men, ≥20% in women). The facility average ADR improved by 7% after the introduction of the CADe system. It is well-established that postcolonoscopy cancers can be attributed to missed lesions. The GI genius CADe system has allowed for better overall ADR and further supports the existing literature, suggesting that adoption of the system may improve detection, and decrease missed lesions. Future investigation can focus on APC since introduction of the CADe system and polypectomy rate, as there is data suggesting a correlation between polypectomy rates and cancer protection.